Literature DB >> 7285268

[Epidemiologic and clinical study of paragonimosis in Cameroon. Results of niclofolan treatment].

C Ripert, J Carrie, P Ambroise-Thomas, R Baecher, N P Kum, A Same-Ekobo.   

Abstract

Paragonimiasis does not occur only in the South West Province of Cameroon. Four foci exist in the country. They are the well known focus in the Mount Kupe area, the Mbam focus, the Nyong focus and the Ntem focus. All of them are located in the rainforest within the distribution area of Potadoma. This disease, characterized by the presence of eggs in sputum and feces, has often been confused with tuberculosis. In the villages where paragonimiasis is diagnosed by means of parasitological techniques circulating antibodies, revealed with a P. westermani antigen (ELISA), are often found in blood specimens taken from inhabitants. Teen agers suffer the most from the disease and females more often than males. Women and children are traditionally concerned with crabs fishing and they eat them after partly raw. Crabs of the genus Sudanautes contain the infective metacercariae. Paragonimiasis is enzootic and the civet cat V. civetta seems to be the main natural definitive host in Cameroon. Niclofolan given orally in a single dose of 2 mg/kg body weight showed a 100% cure rate. Side reactions are mild and transient.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7285268

Source DB:  PubMed          Journal:  Bull Soc Pathol Exot Filiales


  2 in total

1.  Endemicity of Paragonimus and paragonimiasis in Sub-Saharan Africa: A systematic review and mapping reveals stability of transmission in endemic foci for a multi-host parasite system.

Authors:  Muriel Rabone; Joris Wiethase; Paul F Clark; David Rollinson; Neil Cumberlidge; Aidan M Emery
Journal:  PLoS Negl Trop Dis       Date:  2021-02-05

2.  An epidemiological study of pleuropulmonary paragonimiasis among pupils in the peri-urban zone of Kumba town, Meme Division, Cameroon.

Authors:  Roger Moyou-Somo; Charles Kefie-Arrey; Georges Dreyfuss; Michel Dumas
Journal:  BMC Public Health       Date:  2003-12-16       Impact factor: 3.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.